Icosavax Statistics
Share Statistics
Icosavax has 50.23M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 50.23M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,030 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 289.43K, so 0.58% of the outstanding
shares have been sold short.
| Short Interest | 289.43K |
| Short % of Shares Out | 0.58% |
| Short % of Float | 0.97% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -3.57 and the forward
PE ratio is null.
Icosavax's PEG ratio is
0.09.
| PE Ratio | -3.57 |
| Forward PE | n/a |
| PS Ratio | 541.95 |
| Forward PS | n/a |
| PB Ratio | 1.45 |
| P/FCF Ratio | -4.33 |
| PEG Ratio | 0.09 |
Financial Ratio HistoryEnterprise Valuation
Icosavax has an Enterprise Value (EV) of 265.37M.
| EV / Sales | 455.96 |
| EV / EBITDA | -2.79 |
| EV / EBIT | -4.3 |
| EV / FCF | -3.65 |
Financial Position
The company has a current ratio of 16.24,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 16.24 |
| Quick Ratio | 16.24 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.12 |
| Interest Coverage | 28.81 |
Financial Efficiency
Return on Equity is -40.55% and Return on Invested Capital is -40.38%.
| Return on Equity | -40.55% |
| Return on Assets | -37.06% |
| Return on Invested Capital | -40.38% |
| Revenue Per Employee | $9,700 |
| Profits Per Employee | $-1,474,300 |
| Employee Count | 60 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.3M |
| Effective Tax Rate | 3.6% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.28, so Icosavax's
price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 15.45 |
| 200-Day Moving Average | 10.38 |
| Relative Strength Index (RSI) | 55.41 |
| Average Volume (20 Days) | 1,053,296 |
Income Statement
In the last 12 months, Icosavax had revenue of 582K
and earned -88.46M
in profits. Earnings per share was -2.23.
| Revenue | 582K |
| Gross Profit | -1.26M |
| Operating Income | -95.06M |
| Net Income | -88.46M |
| EBITDA | -95.06M |
| EBIT | -95.06M |
| Earnings Per Share (EPS) | -2.23 |
Full Income StatementBalance Sheet
The company has 58.85M in cash and 8.79M in
debt, giving a net cash position of 50.05M.
| Cash & Cash Equivalents | 58.85M |
| Total Debt | 8.79M |
| Net Cash | 50.05M |
| Retained Earnings | -185.83M |
| Total Assets | 251.3M |
| Working Capital | 222.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -61.67M
and capital expenditures -11.11M, giving a free cash flow of -72.79M.
| Operating Cash Flow | -61.67M |
| Capital Expenditures | -11.11M |
| Free Cash Flow | -72.79M |
| FCF Per Share | -1.83 |
Full Cash Flow StatementMargins
Gross margin is -216.67%, with operating and profit margins of -16332.99% and -15198.97%.
| Gross Margin | -216.67% |
| Operating Margin | -16332.99% |
| Pretax Margin | -15765.98% |
| Profit Margin | -15198.97% |
| EBITDA Margin | -16332.99% |
| EBIT Margin | -16332.99% |
| FCF Margin | -12506.53% |
